75496 Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than January 3, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30350 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on October 

27, 2010, Meridian Medical 

Technologies, 2555 Hermelin Drive, St. 

Louis, Missouri 63144, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of 

Morphine (9300), a basic class of 

controlled substance listed in schedule 

II. 

The company manufactures a product 

containing morphine in the United 

States. The company exports this 

product to customers around the world, 

including in Europe. The company has 

been asked to ensure that its product 

sold to European customers meets 

standards established by the European 

Pharmacopeia, which is administered 

by the Directorate for the Quality of 

Medicines (EDQM). In order to ensure 

that its product will meet European 

specifications, the company seeks to 

import morphine supplied by EDQM to 

use as reference standards. This is the 

sole purpose for which the company 

will be authorized by DEA to import 

morphine. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than January 3, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30347 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on October 

19, 2010, Tocris Cookson, Inc., 16144 

Westwoods Business Park, Ellisville, 

Missouri 63021–4500, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in schedule 

I and II: 

Drug Schedule 

Marijuana (7360) .......................... I 

Tetrahydrocannabinols (7370) ..... I 

4–Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

3,4– 

Methylenedioxymethamphetamine (7405).

I 

Amphetamine (1100) .................... II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Diprenorphine (9058) ................... II 

Fentanyl (9801) ............................ II 

The company plans to import small 

quantities of the above-listed controlled 

substances for distribution to its 

customers for non-clinical, laboratorybased research only. 

In reference to drug code 7360 

(Marijuana), the company plans to 

import synthetic cannabinoid agonists. 

In reference to drug code 7370 

(Tetrahydrocannabinols), the company 

will import a synthetic Delta-9–THC. No 

other activity for these drug codes are 

authorized for this registration. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than January 3, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices 75497 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C 958(a); 21 USC 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

DATED: November 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30338 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated March 29, 2010, and 

published in the Federal Register on 

April 16, 2010, 75 FR 20000, Lipomed, 

Inc., One Broadway, Cambridge, 

Massachusetts 02142, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

N–Ethylamphetamine (1475) ........ I 

Fenethylline (1503) ....................... I 

Methaqualone (2565) ................... I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Lysergic acid diethylamide (7315) I 

2,5–Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

3,4,5–Trimethoxyamphetamine 

(7390).

I 

4–Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4–Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4–Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5–Dimethoxyamphetamine 

(7396).

I 

2,5–Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4–Methylenedioxyamphetamine 

(7400).

I 

3,4–Methylenedioxy-Nethylamphetamine (7404).I 

Drug Schedule 

3,4– 

Methylenedioxymethamphetamine (7405).

I 

4–Methoxyamphetamine (7411) ... I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

N–Benzylpiperazine (7493) .......... I 

Acetyldihydrocodeine (9051) ........ I 

Dihydromorphine (9145) ............... I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Pholcodine (9314) ........................ I 

Tilidine (9750) ............................... I 

3–Methylfentanyl (9813) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to import 

analytical reference standards for 

distribution to its customers for research 

and analytical purposes. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Lipomed, Inc. to import the basic 

classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Lipomed, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: November 18, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30334 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on October 29, 2010, 

Siegfried (USA), Inc., 33 Industrial Park 

Road, Pennsville, New Jersey 08070, 

made application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Hydromorphinol (9301), a basic class of 

controlled substance listed in schedule 

I. 

The company plans to manufacture 

small quantities of the listed controlled 

substance in bulk for distribution to its 

customers for use as reference 

standards. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than February 1, 2011. 

Dated: November 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30351 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to 1301.33(a), Title 21 of the 

Code of Federal Regulations (CFR), this 

is notice that on September 13, 2010, 

Chattem Chemicals, Inc., 3801 St. Elmo 

Avenue, Building 18, Chattanooga, 

Tennessee 37409, made application by 

mstockstill on DSKH9S0YB1PROD with NOTICES